Clinical Trials
Our Team
Partners
Categories
Blood
Breast
Lung
Pancreatic
Prostate
Renal
Various

Clinical Trials



If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815.730.3098.

Blood

Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study

Breast

NSABP B-55/ BIG 6-13 : Adjuvant Breast
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

NCT# 02513394 AFT-05, NSABP B-57-I : Adjuvant Breast
Alliance AFT-05: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

A5481082 : Observational: Hormone Receptor Positive Advanced Breast Cancer
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Lung

EA5161 : 1st line extensive stage SCLC
Study: Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)

S1400 : SCLC
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Pancreatic

RX3117-003 : First-Line Metastatic Pancreatic
RX3117-003 - A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination with AbraxaneŽ in Subjects with Metastatic Pancreatic Cancer

Prostate

EA8153 : 2nd line Metastatic Prostate
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

Renal

E7080-G00-307 : Advanced Renal Cell
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma

Various

Exact Sciences 2018-01 : Biomarkers on Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors: Breast, Lung, Coorectal, Prostate, Bladder, Uterine, Kidney/Renal Pelvis, Pancreatic, Liver, Stomach, Ovarian or Esophageal

MIT-201701 : CANscript Observational Various Solid Cancers
Various types of advanced solid cancer (e.g. squamous cell carcinoma of the head and neck (HNSCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), and colorectal cancer (CRC)



Our Team


President:
Dr. Kulumani M. Sivarajan, MD

Medical Director of Clinical Research:
Dr. Nafisa Burhani, MD

Manager of Clinical Research:
Karen Sceniak, CCRC
ksceniak@jolietoncology.com

Clinical Research Coordinators:
815-730-3098
Maureen Clennon
maureenc@jolietoncology.com

Tonya Finger
tfinger@jolietoncology.com

Data Manager:
Jennifer Crocker
jennifercrocker@jolietoncology.com

Regulatory Affairs Manager:
Joan Pufahl
joanp@jolietoncology.com

Partners